Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M V Mateos

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Leukemia|August 9, 2014
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasoneE M Ocio, D Fernández-Lázaro, L San-Segundo, et al.
Leukemia|October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisN C Gutiérrez, M V Castellanos, M L Martín, et al.
Leukemia|July 18, 2013
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometryN Puig, M E Sarasquete, A Balanzategui, et al.
Leukemia|November 4, 2017
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trialsP Arana, B Paiva, M-T Cedena, et al.
Leukemia|June 8, 2013
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease controlB Paiva, M-B Vídriales, L Rosiñol, et al.
Leukemia|February 16, 2012
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patientsB Paiva, N-C Gutiérrez, X Chen, et al.
Leukemia|November 13, 2014
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potentialT Paíno, B Paiva, J M Sayagués, et al.
Leukemia|February 18, 2017
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaJ Martinez-Lopez, B Sanchez-Vega, S Barrio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcomeM Constans, A Sureda, M J Terol, et al.
Leukemia|January 22, 2011
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myelomaB Paiva, M Pérez-Andrés, M-B Vídriales, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Leukemia|August 9, 2014
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasoneE M Ocio, D Fernández-Lázaro, L San-Segundo, et al.
Leukemia|October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisN C Gutiérrez, M V Castellanos, M L Martín, et al.
Leukemia|July 18, 2013
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometryN Puig, M E Sarasquete, A Balanzategui, et al.
Leukemia|November 4, 2017
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trialsP Arana, B Paiva, M-T Cedena, et al.
Leukemia|June 8, 2013
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease controlB Paiva, M-B Vídriales, L Rosiñol, et al.
Leukemia|February 16, 2012
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patientsB Paiva, N-C Gutiérrez, X Chen, et al.
Leukemia|November 13, 2014
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potentialT Paíno, B Paiva, J M Sayagués, et al.
Leukemia|February 18, 2017
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaJ Martinez-Lopez, B Sanchez-Vega, S Barrio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcomeM Constans, A Sureda, M J Terol, et al.
Leukemia|January 22, 2011
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myelomaB Paiva, M Pérez-Andrés, M-B Vídriales, et al.
Pageof 8